2023 World Conference on Lung Cancer (Posters)-EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer.

EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer. - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers at Kansai Medical University in Japan aimed to investigate the agreement among different programmed cell death ligand-1 (PD-L1) immunohistochemistry results using different antibodies for lung cancer. The study included 416 cases of completely resected non-small cell lung cancer (NSCLC) patients. The antibodies used for evaluation were 73-10, 22C3, and 28-8. The results showed high overall percent agreement (OPA) between 73-10 and both 22C3 and 28-8. However, the results of positive percent agreement (PPA) and negative percent agreement (NPA) indicated that 28-8 results could not be translated to those of 73-10. The study also mentioned limitations including its retrospective and single institutional nature, small sample size, lack of data on gene alteration, and the fact that 73-10 was evaluated by a single pathologist. The study concluded that there is a high agreement between 73-10 and both 22C3 and 28-8, and the results of 73-10 may be translated to those of 22C3 or 28-8, but not vice versa. This study contributes to the understanding of the agreement among PD-L1 immunohistochemistry results using different antibodies for lung cancer.

Asset Subtitle

Tomohito Saito

Meta Tag

Speaker Tomohito Saito

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

Kansai Medical University

PD-L1 immunohistochemistry

lung cancer

NSCLC

antibodies

73-10

22C3

28-8

percent agreement

gene alteration